FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today the expansion of its capabilities in business and commercial development. Ashley Lawton, Ph.D., GTC’s new Vice President of Business Development, will focus primarily on additional strategic partnering for our proprietary programs, including monoclonal antibodies, as well as developing partners for follow-on biologics. Rick Finnegan, GTC’s new Vice President of Commercial Development, will focus on market introduction strategies for our products, including through partners.
